chlorpromazine has been researched along with pirenzepine in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 16 (59.26) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Barrantes, MA; Blosser, JC; Manian, AA; McCreedy, SA; Palmer, GC | 1 |
| Debing, I; Ijzerman, AP; Vauquelin, G | 1 |
| Chung, C; Cook, P; Pendleton, RG; Risley, E; Williams, M | 1 |
| Meyer, JM; Simpson, GM | 1 |
| Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S | 1 |
| De Bittencourt, PR; Hanel, RA; Kranich, M; Sandmann, MC | 1 |
| Farver, D; Khan, M | 1 |
| McCallum, SE; Porter, JH; Vann, RE; Varvel, SA | 1 |
| Kameda, K; Koyama, T; Kusumi, I; Suzuki, K; Takahashi, Y | 1 |
| Mueser, KT; Noordsy, DL; O'Keefe, C; Xie, H | 1 |
| Copolov, DL; Dean, B; Hussain, T; Pavey, G; Scarr, E | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Dean, B; Parkin, FM; Pavey, G; Scarr, E | 1 |
| Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Woods, SW | 1 |
2 review(s) available for chlorpromazine and pirenzepine
| Article | Year |
|---|---|
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Male; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors | 2000 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
2 trial(s) available for chlorpromazine and pirenzepine
| Article | Year |
|---|---|
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Chlorpromazine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Headache; Humans; Male; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Sleep Stages; Treatment Outcome; Xerostomia | 1998 |
Six-month outcomes for patients who switched to olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Chlorpromazine; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2001 |
23 other study(ies) available for chlorpromazine and pirenzepine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Correlation of activity of chlorpromazine and respective hydroxy, dimethoxy and sulphoxide analogues on dopamine, muscarinic, histamine and calmodulin sites of action.
Topics: Adenylyl Cyclase Inhibitors; Animals; Binding Sites; Calmodulin; Cerebral Cortex; Chlorpromazine; Cyclic AMP; Dopamine; Histamine; Hypothalamus; Phosphoric Diester Hydrolases; Pirenzepine; Rats; Receptors, Dopamine; Receptors, Muscarinic; Spiperone; Sulfoxides | 1988 |
Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity.
Topics: Animals; Cattle; Chloroquine; Chlorpromazine; Electron Transport; Kinetics; Levodopa; Melanins; Melanocytes; NAD; Oxidation-Reduction; Pirenzepine | 1988 |
Comparison of central gastric antisecretory effects of desmethylimipramine, doxepin and pirenzepine in rats.
Topics: Animals; Anti-Ulcer Agents; Atropine; Benzodiazepinones; Brain; Chlorpromazine; Desipramine; Doxepin; Gastric Acid; Male; Pirenzepine; Rats; Rats, Inbred Strains | 1984 |
From chlorpromazine to olanzapine: a brief history of antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; History, 20th Century; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1997 |
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Recurrence | 1998 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Olanzapine; Pirenzepine; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Ritanserin; Scopolamine | 2000 |
Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Chemistry; Chlorpromazine; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Indoles; Isoindoles; Male; Olanzapine; Pirenzepine; Protein Binding; Quinolines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2000 |
Atypical antipsychotic drugs: how much better are they?
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Pirenzepine | 2001 |
Olanzapine: new preparation. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Humans; Pirenzepine; Risperidone; Schizophrenia; Treatment Outcome | 1999 |
Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
Topics: Animals; Antipsychotic Agents; Benzamides; Benzazepines; Benzodiazepines; Chlorpromazine; Clozapine; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Male; Muscimol; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, GABA-A | 2001 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Haloperidol; Ion Channels; Male; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlorpromazine; Clozapine; Diabetes Mellitus; Glucose Intolerance; Haloperidol; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Risk Factors; Risperidone; World Health Organization | 2002 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |